Tawesak Tanwandee
Overview
Explore the profile of Tawesak Tanwandee including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
100
Citations
2441
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Malik J, Klammer M, Rolny V, Chan H, Piratvisuth T, Tanwandee T, et al.
World J Gastroenterol
. 2022 Sep;
28(29):3917-3933.
PMID: 36157551
Background: Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. Current guidelines for HCC management recommend surveillance of high-risk patients every 6 mo using ultrasonography. Serum biomarkers,...
22.
Chirapongsathorn S, Teerasarntipan T, Tipchaichatta K, Suttichaimongkol T, Chamroonkul N, Bunchorntavakul C, et al.
JGH Open
. 2022 Mar;
6(3):205-212.
PMID: 35355669
Background And Aim: Acute-on-chronic liver failure (ACLF) leads to multi-organ failure related to high mortality rates. This study aimed to gather epidemiological data and validate a scoring system to predict...
23.
Sirisunhirun P, Bandidniyamanon W, Jrerattakon Y, Muangsomboon K, Pramyothin P, Nimanong S, et al.
BMC Gastroenterol
. 2022 Feb;
22(1):66.
PMID: 35164698
Background: Physical inactivity and sarcopenia are two important predictors associated with increased morbidity and mortality in patients with cirrhosis. At present, the benefit of a home-based exercise training program is...
24.
Dilokthornsakul P, Sawangjit R, Tangkijvanich P, Chayanupatkul M, Tanwandee T, Sukeepaisarnjaroen W, et al.
Appl Health Econ Health Policy
. 2022 Feb;
20(4):587-596.
PMID: 35141850
Background: Nucleos(t)ide analogues (NAs) are the main drug category used in the treatment of chronic hepatitis B (CHB). There is a need to update the economic evaluation of CHB treatment....
25.
You H, Ma X, Efe C, Wang G, Jeong S, Abe K, et al.
Hepatol Int
. 2022 Feb;
16(1):1-23.
PMID: 35119627
No abstract available.
26.
Kumar M, Abbas Z, Azami M, Belopolskaya M, Dokmeci A, Ghazinyan H, et al.
Hepatol Int
. 2022 Feb;
16(2):211-253.
PMID: 35113359
Hepatitis B virus (HBV) infection still remains a major public health issue in the Asia-Pacific region. Most of the burden of HBV-related disease results from infections acquired in infancy through...
27.
Lau G, Yu M, Wong G, Thompson A, Ghazinian H, Hou J, et al.
Hepatol Int
. 2022 Jan;
16(2):486-487.
PMID: 35076895
No abstract available.
28.
Phisalprapa P, Tanwandee T, Neo B, Singh S
Medicine (Baltimore)
. 2021 Dec;
100(51):e28308.
PMID: 34941122
This study aimed to quantify and evaluate the knowledge and awareness toward liver health and diseases as well as explore the attitudes and knowledge toward screening, diagnosis, and treatment of...
29.
Lee M, Ahn S, Chan H, Choudhry A, Gani R, Mohamed R, et al.
J Viral Hepat
. 2021 Nov;
29(2):156-170.
PMID: 34817896
There are limited data to provide better understanding of the knowledge/awareness of general population towards liver health in Asia. We sought to identify the knowledge gaps and attitudes towards liver...
30.
Piratvisuth T, Tanwandee T, Thongsawat S, Sukeepaisarnjaroen W, Esteban J, Bes M, et al.
Hepatol Commun
. 2021 Nov;
6(4):679-691.
PMID: 34796691
Hepatocellular carcinoma (HCC), the sixth most common cancer worldwide, has an incidence rate equal to mortality. Over 80% of HCC cases occur within a high-risk population, mainly patients with both...